ClinicalTrials.gg
Active, not recruitingNCT06850896Updated Feb 28, 2025

Antibiotic Exposure on Gut Microbiota and Motility Establishment in Newborns

An observational study in NEC - Necrotizing Enterocolitis, sponsored by The First Hospital of Jilin University. Active, not recruiting at 1 site in China. Open to participants aged 24 Weeks to 36 Weeks. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by The First Hospital of Jilin University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
24 Weeks to 36 Weeks
Sex
All
01

Study summary

This prospective cohort study aims to investigate the impact of early antibiotic exposure on the establishment of gut microbiota and motility in newborns, particularly preterm infants. The study will explore the correlation between antibiotic exposure, gut microbiota colonization, and 5-hydroxytryptamine (5-HT) levels, which are critical for gastrointestinal motility. The findings may provide insights into optimizing antibiotic use and improving gastrointestinal health in neonates.

02

Conditions studied

  • NEC - Necrotizing Enterocolitis
03

In context

Enterocolitis, Necrotizing

228 studies on the registry are indexed under Enterocolitis, Necrotizing; 44 are open to participants now.

This study's planned enrollment of 200 is above the median of 144 across 95 observational studies indexed under Enterocolitis, Necrotizing.

Browse Enterocolitis, Necrotizing studies →

Lead sponsor

The First Hospital of Jilin University is the lead sponsor of 185 studies on the registry; 96 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Weeks to 36 Weeks
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will enroll newborns admitted to the neonatal unit of Jilin University First Hospital from November 2024 to November 2027.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newborns admitted within 72 hours of birth
  • Gestational age 24-36 weeks (preterm) and term infants
  • obtained from parents or guardian

Exclusion criteria

Exclusion Criteria:

  • Congenital gastrointestinal malformations (e.g., intestinal atresia, Hirschsprung's disease)
  • Severe systemic or organ-specific diseases
  • Expected mortality due to severe illness
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Preterm Infants with Antibiotic Exposure

    Description: Newborns with gestational age 24-36 weeks who receive antibiotics within the first 72 hours of life.

06

What researchers measure

Primary outcomes

  1. gut microbiota

    Impact of antibiotic exposure on gut microbiota colonization assessed by 16S rRNA sequencing.

    Time frame: Enrollment Period: This is the time during which participants will be recruited and enrolled into the study. You have specified that enrollment will occur from November 2024 to November 2027. Intervention Period: Since this is an observational study, the

07

Study locations

1 site
08

References and documents

Publications

  • Jiang S, Zhang L, Yan W, Li S, Han J, Zhou Q, Yang Y, Lee SK, Cao Y; REIN-EPIQ Study Group. Antibiotic Use in Neonatal Intensive Care Units in China: A Multicenter Cohort Study. J Pediatr. 2021 Dec;239:136-142.e4. doi: 10.1016/j.jpeds.2021.08.067. Epub 2021 Aug 28. PubMed 34461063 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for May 2027, 27 months after the start.

Of 39 observational studies under Enterocolitis, Necrotizing, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 115. This study's planned 27 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2025
First posted
Feb 28, 2025
StartActual
Feb 1, 2025
Primary completionEst.
May 30, 2027
CompletionEst.
May 30, 2027
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06850896
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
Feb 1, 2025
Primary completion
May 30, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Feb 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion